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Introduction
RhoA is a founding member of the Rho GTPase family and serves as an intracellular molecular switch, cycling between a GTPbound, active form and a GDP-bound, inactive form. RhoA activity and intracellular localization are primarily regulated by guanine nucleotide-exchange factors (GEFs), GTPaseactivating proteins (GAPs) and guanine nucleotide-dissociation inhibitors (GDIs). GEFs catalyze the release of GDP from RhoA and thereby promote GTP binding to RhoA. GAPs stimulate the intrinsic GTPase activity of RhoA, causing the hydrolysis of GTP and RhoA inactivation. GDIs inhibit the dissociation of GDP from RhoA, and also extract RhoA from membrane where RhoA executes its biological functions. Through direct interaction with downstream effectors, activated RhoA transduces signals and regulates multiple cellular processes (1) . RhoA is critical for several fundamental cell functions including migration, adhesion, survival, cell division, gene expression, and vesicle trafficking (1) (Fig. 1) .
In this review, we describe recent progress in studying RhoA signaling in mammalian physiology using mouse genetic models, especially conditional RhoA knockout mice and RhoA regulator or effector gene targeted mice. Similar with what we have learned by mouse gene targeting studies of other Rho GTPase family members such as Cdc42 and Rac (2-4), the mouse model work of RhoA signaling confirms some conclusions of earlier in vitro studies, but more importantly they shed light onto novel, cell type-specific signaling roles of RhoA under diverse physiologic conditions. 2 signaling network can be altered in immortalized cells and by in vitro conditions.
In addition, the tools used in cell culture systems to study RhoA signaling also have limitations. A commonly used approach to manipulate RhoA activity is through dominant mutant overexpression. The use of the mutants may elicit off-target effects, as they are often overexpressed over endogenous RhoA level and can tie up multiple regulatory GEFs or GAPs to affect other related Rho GTPase signaling activities, or affect the dynamics of effector interactions at precise intracellular locations. Another tool for studies of RhoA signaling has been the Clostridium botulinum C3 exoenzyme (C3) toxin, which ADP-ribosylates the conserved Asn-41 residue of Rho GTPase subfamily members (RhoA, B and C), thereby inactivating their effector-binding domain (5, 6) . Although it shows reduced ability in inactivating other Rho GTPases (e.g., Rac1 and CDC42), C3 toxin is not useful for dissecting the RhoA function from that of RhoB or RhoC (5,6) which might be involved in distinct signaling functions (7) , and may affect non-Rho signaling such as cJun N-terminal Kinase (JNK) and p38 (8) with a toxic effect (9) . Thus, caution needs to be applied in interpreting cell biological results obtained by these approaches.
Signaling role of RhoA revealed by gene targeting in mice
Considering the limitations of conventional methods in studying RhoA signaling function, genetic manipulation of RhoA is superior in understanding the bona fide role of RhoA in individual tissue/cell types. Recently several labs have generated conditional RhoA knockout mouse models. These RhoA loss of function mouse models help confirm some previously observed RhoA cellular functions. Significantly, they have also revealed some unexpected roles of RhoA in specific cell types under varying physiologic conditions ( Table 1) .
Mouse embryonic fibroblasts (MEF)
Significant knowledge about RhoA cellular function derives from earlier studies in fibroblast cell lines. Dominant RhoA mutant overexpression or C3 toxin treatment showed that RhoA is essential for the organization of actomyosin network and for focal adhesion (1) . Subsequent rhoB or rhoC mouse knockout studies found no such phenotypes (10,11); therefore, it has been postulated that RhoA is the major regulator of actomyosin and focal adhesion dynamics among Rho GTPases. Surprisingly, recent studies of the rhoA null MEF cells found no actomyosin or focal adhesion defects (12) . Consistently, deletion of rhoA did not alter the activity of downstream signaling targets, the actomyosin machinery myosin light-chain (MLC) and cofilin, nor MAL-/SRF-mediated transcription, a pathway known to depend on F-actin dynamics (1) . A significant increase of RhoC expression and activity was observed in RhoA null MEF cells. Furthermore, deleting of rhoC in combination with a knocking down of RhoB in rhoA null MEF cells fully disrupted the formation of stress fibers and focal adhesion, indicating a redundancy of RhoA, RhoB and RhoC in the regulation of cytoskeletal organization and cellextracellular matrix interaction ( Fig. 2A) .
RhoA was found required for cell cycle progress at G 1 /S phase transition and cytokinesis (13, 14) , and for controlling cell cycle regulator p21
Cip and p27 Kip1 expression or stability (15, 16) . In rhoA-null MEF cells, cell cycle G 1 /S phase progression as well as the p21
Cip1 and p27
Kip1
expressions appeared normal, but cytokinesis is defective, despite the unaltered MLC activity (12) . Therefore, RhoA seems to control cytokinesis by utilizing a signaling pathway parallel to MLC activity. In addition, despite a high degree of conservation in sequence and subcellular localization among RhoA, RhoB and RhoC (7), a RhoA-unique pathway must regulate cytokinesis ( Fig. 2A) . It will be interesting to pinpoint such a mechanism.
Skin development and maintenance
Mutant overexpression and inhibitor studies in cultured keratinocyte cell lines have shown that RhoA signaling is essential for regulating skin cell proliferation, differentiation (17) , and cell-cell contacts (18) . Different from the MEF cells (12) , Keratin-5 Cre-driven rhoA deletion in keratinocytes in vivo was sufficient to reduced phosphorylation of MLC and cofilin (19) . Primary keratinocyte culture showed additional defects upon rhoA deletion: impaired junction 3 maturation, a mild cytokinesis defect, and decreased directional migration. However, rhoA deletion did not affect development of epidermis or hair follicles, nor the formation and maintenance of cell-cell contacts, including adherens junctions and tight junctions, in vivo. Further, no cytokinesis defects were detected in RhoA null keratinocytes in vivo (19) , and functionally, the RhoA deficient epidermis displayed no defects in wound healing. The discordance between in vivo and in vitro knockout studies may be attributable to compensation by the related RhoB, since RhoA deficiency increased RhoB expression in the keratinocytes. These data, along with the observed differences between MEFs and keratinocytes, indicate that RhoA signaling and function are cell context dependent -thereby emphasizing the influence of environment on cell signaling mechanisms.
Cardiovascular regulation
RhoA's role in regulating cardiac physiology and pathophysiology remains largely unclear. On one hand, RhoA activity is increased by insults such as H 2 O 2 , glucose deprivation, and ischemia/reperfusion (I/R) (20) . Modest expression of constitutively active RhoA activates PKD, which appears to be beneficial to protect against injuries (i.e., I/R) (21) . On the other hand, overexpression of RhoA in cardiomyocytes induces apoptosis by upregulating Bax (22) . Further, prolonged expression of active RhoA during development results in hypertrophy (21) , and pharmaceutical inhibition of its effector ROCK suppresses hypertrophy induced by pressure-overload (23) . Knockout studies implicate the cardio supportive function of RhoA. Hearts of cardiac-specific rhoA knockout mice, driven by βMHC-Cre, had significantly increased LDH release and infarct size after I/R challenge (21) . Similarly, PKD phosphorylation was diminished. Thus, RhoA protects heart against ischemia/reperfusion damage through PKD, and is important to prevent LDH release and heart infarct (Fig. 2B) .
Eye development
Apical constriction of epithelial cells, which is commonly observed during development processes including gastrulation, neural tube folding, and lens placode invagination (24) , is driven by polarized contraction of the actomyosin cytoskeleton at the apical side of epithelial cells (25) . RhoA and its downstream signaling components such as ROCK and MLC were shown to be apically enriched during the apical constriction of epithelial tissues such as lens placode, and inhibition of RhoA pathway via inhibitors reduced apical constriction (26) . Consistently, Le-Cre-driven deletion of rhoA in lensepithelium impaired apical constriction(27). In the apical half of the cell, rhoA deletion led to decreased MLC activity, and decreased the contraction force necessary for constriction. In the basal half, distribution of Rac1 and its downstream effector Arp2/3 were expanded, leading to protrusion of actin filament and cell elongation (27). Thus, RhoA regulates lens epithelium morphology by activating MLC and actomyosin contractility at the apical half and restricting Arp2/3 activity and polymerization of protrusive actin at the basal half (Fig. 2C) .
Another aspect of eye development regulated by RhoA is transient closure of eyelids. Normally, mice are born with closed eyelids and this is maintained before postnatal day 12 (28) . Deletion of ROCK 1 or 2, or mutation of MAP3K1 (a downstream target of RhoA-ROCK, results in an eye open-at-birth (EOB) phenotype (29, 30) . Interestingly, deletion of rhoA within eyelid epithelium driven by Lecre does not impair eyelid development. However, in Map3k1 hemizygotic background, conditional deletion of rhoA delayed eyelid closure, possibly through regulation of MAP3K1 expression (31) .
Nervous system
Neural development is a complex process involving the proliferation, differentiation and migration of neurons and their supporting glia (32) (33) (34) , and RhoA may be involved in all these functions (1). To form proper neural circuits, neurons must also form axons, which extend over sometimes long and complicated paths to connect with specific target cells (35) . Actin cytoskeletal dynamics plays a key role in axon growth and guidance, and in vitro studies have shown that RhoA activity increases actomyosin 4 contractility and induces collapse of the growth cone and repulsion of the axons (36) .
The function of RhoA in regulating adherens junctions in the central nervous system has been studied using several cell-type specific Cre transgenic models, e.g., driven by Wnt1-cre in mesencephalon, Foxg1-Cre and Brn4-Cre in forebrain, and Olig2-Cre in spinal cord. Deletion of rhoA results in dysplasia and disrupts the distribution of adherens junction components such as N-cadherin, αE-catenin, β-catenin, and F-actin (37) (38) (39) . In rhoA knockouts, rosette-like structures -seen previously in N-cadherin null mutants (40) -were observed in brain and spinal cord, and cells were found to invade in the lumen of the neural tube (38) , suggesting disturbance of adherens junctions and disruption of cell-cell contact in the neuroepithelium.
Although RhoA appears to have a similar role in regulating cell-cell contact in brain and spinal cord, it has differential functions in regulating the proliferation of these two central nervous system tissues. Brain-specific deletion of rhoA (driven by Wnt1-Cre or Foxg1-Cre) caused expansion of neural progenitor cells as a result of increased proliferation and reduced cell-cycle exit (37) ; this is similar to αE-catenin knockout brains (41) .
In a sharp contrast, spinal-cord-specific deletion of RhoA (driven by Brn4-Cre) reduced neuron proliferation and caused precocious cell-cycle exit -perhaps as a result of premature differentiation of neural progenitor cells (38) . Interestingly, phosphohistone3-labeled mitotic cells dispersed throughout the neuroepithelium in RhoAdeficient brain and spinal cord, instead of the tight luminal localization in wild-type neural tube (37, 38) , suggesting an alteration of neural progenitor niche.
The function of RhoA in regulating neural circuit organization has also been intensively investigated. Deletion of rhoA in ventral or dorsal spinal cord motor neuron progenitors by Olig2-Cre or Wnt1-Cre resulted in a rabbit-like hopping gait, a typical locomotor circuitry disruption phenotype. Hopping phenotypes were also documented in mutant mice for axon outgrowth repellant ephrinB3 or its receptor EphA4 (42) (43) (44) . EphrinB3 is highly expressed at the midline of developing spinal cord, and it prevents axon expressing its receptor, EphA4, from crossing the midline (43, 45) . The axons do, in fact, cross the midline in ephrinB3-or EphA4-mutant mice, leading to a disruption of locomotor circuitry (42, 44) . Axons of RhoAdeficient corticospinal neurons and interneurons display a similar midline-crossing phenotype, as well as a loss of ephrinB3 expression at the spinal cord midline, causing a deficiency in ephrinB3-EphA4 signaling (38) . In contrast to corticospinal neurons or interneurons, the central and peripheral projections of RhoA-null (driven by Wnt1-Cre) dorsal root ganglia (DRG) neurons appear normal (46) . Consistently, Sema3-mediated axon repulsion, a process previously described as RhoA-dependent behavior (47) , was maintained in RhoA-null DRG neurons in vitro. This could be due to a compensation by RhoC, expression of which was significantly increased in RhoA-null DRG neurons.
During neocortical development, neurons are sorted into six horizontal layers and neurons generated in the proliferative zones migrate to their destinations in the cortex. (33) . Deletion of rhoA in cerebral cortex (driven by Emx1-Cre) resulted in two migrational phenotypes by two different mechanisms. In the first, RhoA null neurons migrated faster than wild-type cellswith some mutant cells migrating to the pial surface and resembled the cobblestone lissencephaly phenotype. In the second phenotype, heterotopic cortex is generated underneath normatopic cortex, as in subcortical band heterotopia (SBH) (48) . This SBH phenotype appears to be due to cytoskeletal defects within radial glia -rather than neurons themselves. RhoA-null neurons transplanted into wild-type cortex migrated normally, but not the other way around. The radial glial scaffold was severely disrupted after loss of RhoA: cell somata scattered rather than tightly aligned; processes were disorganized and no longer connected the upper and lower halves of the cerebral cortex. Furthermore, severe disruptions in both actin and microtubule cytoskeletons were observed in radial glial cells and this might be the underlying mechanism for the SBH phenotype. The hematolymphoid system is derived from primitive hematopoietic stem and progenitor cells (HSPCs). Inhibition of RhoA activity, by overexpressing dominant-negative RhoA mutant, enhances HSPC proliferation and engraftment (49) . On the other hand, increased RhoA activity, by knocking out of one of the major RhoA GAPs in the primitive HSPCs (p190-B), also enhanced HSPC engraftment (50) . These observations made it difficult to interpret the role of RhoA in regulating HSPC from the suppression of function and gain of function models. In contrast, loss of rhoA in hematopoietic lineages driven by Mx1-Cre resulted in complete disruption of hematopoiesis and pan-cytopenia. Interestingly, only blood progenitors, rather than hematopoietic stem cells (HSCs), were severely affected by the loss of RhoA. RhoA null HSCs retained the ability to compete with wild-type counterparts, while the progenitors could not. Consistently, rhoA -/-hematopoietic progenitor cells, rather than HSCs, displayed a significantly increased TNFα-mediated necrosis and cytokinesis failure (Fig.  2E) (51) . Within the blood progenitor populations, RhoA knockout reduced MLC activity, which is thought to be indispensable for cytokinesis (14) ; however, it remains to be determined whether this contributed to the cytokinesis failure phenotype.
Hematolymphoid system regulation
G-protein-coupled receptor (GPCR) agonists (e.g., thrombin, ADP, and thromboxane) are important for regulating the behavior of megakaryocyte-platelet lineage (52) . G 13 , a major RhoA activator (53) , is critical for shape change of platelets, and the G 13 -RhoA-ROCK axis is involved in platelet activation (54) . Deletion of rhoA by PF4-Cre led to accumulation of megakaryocytes and reduction of platelets, indicating a blockage of the final step of thrombopoiesis (55) . rhoA-deleted platelets displayed reduced responses to agonists of G 13 and, to a lesser extent, G q signaling However, no defects in actin assembly were observed in RhoA-depleted platelets, which resembled the case in rhoA-deleted keratinocytes or MEFs. However, different from keratinocytes or MEFs in which a compensatory increase of RhoB or RhoC expression was observed after deletion of RhoA (19), RhoA is the major Rho subfamily protein expressed in platelets (56) and it is unlikely that RhoB or RhoC can compensate for the deletion of RhoA. rhoA deleted platelets also displayed reduced integrin-mediated clot retraction but normal spreading on fibronectinan interesting result, given that both functions are downstream of integrin outside-in signaling.
It (57) . Deletion of rhoA in the entire hematopoietic lineages (driven by Mx1-Cre) increased CLP cells, but significantly reduced proB, preB and immature B cells in the bone marrow (58) , resembling the blockage of megakaryocytes/platelets differentiation (55) . In contrast, deletion of rhoA from the B-cell lineage by CD19-Cre did not alter numbers of proB, preB or immature B cells in bone marrow -possibly due to poor deletion efficiency of CD19-Cre in the bone marrow (58, 59) . In spleen, rhoA deficiency resulted in significant reductions in T, MZ and FO B cells -not because of impaired proliferation, but rather reduced survival. Indeed, deletion of rhoA decreased transcription of receptor for B-cell survival factor, BAFF, and thus blunted response to BAFF-induced inhibition of apoptosis (58) .
Signaling function of RhoA revealed by gene targeting regulators or effectors in mice
Complementing the rhoA gene targeting studies, recent work specifically deleting selected RhoA regulator or effector genes in mice have also contributed to our understanding of RhoA signaling function in vivo ( Table 2) .
RhoA activity is primarily regulated by three classes of regulators, i.e. GEFs, GAPs and GDIs. While expression of some RhoA regulators is ubiquitous (e.g., Dlc-1(60) and p190 (61)), many are tissue and cell type 6 specific (e.g., Rgnef (62) ,mgcRacGAP (63) and p190B (64) ). RhoA activity in a given cell may result from a combined effect of the various regulators expressed in the cell. In addition, while some GEFs and GAPs may signal specifically through RhoA, others may regulate multiple Rho GTPase family members (53, 65, 66) . Thus, depending on the expression pattern of various regulators and potential crosstalk with other Rho GTPases, deletion of a given RhoA regulator may or may not result in a similar phenotype as the rhoA knockout. For example, knocking out the GEF ect-2 in MEF cells leads to a cytokinesis failure (67) similar to that of rhoA gene deletion (12) , but no detectable cytokinesis defects were seen in other GEF knockout MEFs. Interestingly, deletion of the GAP mgcRacGAP also caused cytokinesis failure (63, 68) , indicating that RhoA activity is tightly controlled by the mgcRacGAP and ect-2 GAP/GEF pair during cytokinesis. In another example, deletion of the GAP p190 blocked callosal axons from crossing the midline (69), which is consistent with the aberrant midline crossing of axons of corticospinal neurons and interneurons in RhoA deleted mice (39) , suggesting that the p190 regulated RhoA activity controls this axon behavior. In contrary, some knockout models of RhoA regulators also display distinct phenotypes from RhoA knockout mice. For example, different from RhoA knockout in MEF cells (12) , deletion of the GEF Rgnef blocked focal adhesion formation (62). As mentioned above, deletion of the GAP p190B, a major negative regulator of RhoA led to increased long-term HSC activity and reduced progenitor activities (50), whereas rhoA knockout resulted in a differentiation block from HSC to blood progenitors. It is possible that in a complex process such as hematopoiesis, RhoA activity is tightly regulated by the interplay of multiple regulators. Further, in addition to RhoA, the regulators may also control the activities of other Rho GTPases or signaling components in a defined cell lineage. Gene targeting studies of specific RhoA regulators can be complementary to rhoA knockout studies for delineating cell type specific signaling module of RhoA.
Activated RhoA executes its function by recruiting downstream effectors (Fig. 1) . Like RhoA regulation by multiple regulators, engagement of the effectors by RhoA may be complicated by the expression pattern of effectors and possibly a shared involvement by related Rho GTPases. Not surprisingly, effector knockout and RhoA knockout mouse models have been reported to show both consistent and discordant phenotypes.
For example, neuroepithelial integrity was impaired in both RhoA and mDia knockouts (37, 38, 70) , suggesting that the RhoA-mDia axis might be critical in regulating adherens junction in developing central nervous system. In contrast, while rhoA-deleted central nervous system showed no obvious cytokinesis defects, knocking out citron kinase in mice caused a severe cytokinesis blockage (71) . Similarly, deletion of rhoA in the hematopoietic lineage caused pancytopenia and blockage of differentiation at the HPC stage, whereas mDia deletion resulted in reduced T-cell lineage and myeloproliferative phenotype (72, 73) . Deficiency in Rho kinases, a major class of effectors of RhoA, can also cause different phenotypes from RhoA knockout in mice. For example, in contrast to the RhoA knockout eyelid epithelium, in which a EOB phenotype was only evident in Map3k1 hemizygotic background (31) , deletion of either ROCK-I or -II induced EOB (29, 74) , suggesting that other signaling input to ROCKs, in addition to RhoA, is important for regulating eyelid closure. In blood monocytes, ROCK-I binds directly to the tumor suppressor PTEN to regulate PTEN mediated PIP3, Akt and cyclin D1 pathway and cell migration (75) . Therefore, in addition to the possibility of combined activities of multiple RhoA effectors in a certain tissue, interplays among different effectors, which can also subject to RhoA-independent signal regulation, may play a compensatory or combinatory role downstream from RhoA. It remains a challenge to sort out which effector pathway(s), e.g. RhoA-ROCK, RhoA-mDia and/or RhoA-citron, is engaged by RhoA to mediate a signaling function. The gene targeting studies also suggest that potential therapeutic effects of effector inhibition, such as by ROCK inhibitors, do not necessarily phenocopy RhoA inhibition in applications.
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Conclusions
In addition to previous cell biological studies, genetic studies in lower organisms such as the yeast Saccharomyces cerevisiae and the fruit fly Drosophila melanogaster have implicated RhoA orthologs in key processes of organismal viability and morphogenesis (76) (77) (78) . The recently developed genetic mouse models of RhoA, coupled with RhoA regulator/effector mouse gene targeting efforts, help establish RhoA as an essential signal transducer required for the survival and several fundamental behaviors of mammalian cells. Importantly, the mouse model studies indicate that RhoA can play an essential, non-redundant role in one signaling function in a given cell type while being dispensable for a similar function or involved in a different function in another cell type. The cell-type specificity may reflect a pathway-specific nature of RhoA signaling module and its cross talk with other related Rho GTPases, similar to the cases of Cdc42 and Rac (2-4).
Despite considerations associated with mouse gene targeting approach due to compensatory signaling, the mouse knockout studies offer an improved method in deciphering the physiologic function of RhoA in mammal tissues. Future studies will better define the interaction between RhoA and its specific regulators and effectors in vivo in formulating a more comprehensive RhoA signaling module under each unique cell type and tissue environment. In addition, the mouse genetic studies may reveal information about possible involvement of RhoA signaling in human diseases, and the RhoA and its regulator/effector knockout mice will be useful for an evaluation of the contribution of RhoA signaling in pathophysiology. To this end, abnormal RhoA signaling has been associated with human cancer, neuronal disorders, and asthma (20, 79, 80) , and rational design and targeting of RhoA signaling pathway (81-84) may bear therapeutic value.
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2. The abbreviations used are: C3, C3 exoenzyme; CLP, common lymphoid progenitor; DRG, dorsal root ganglia; EOB, eye open-at-birth; FO, follicular; GAP, GTPase-activating protein; GDI, guanine nucleotide-dissociation inhibitor; GEF, guanine nucleotide-exchange factor; GPCR, G-protein-coupled receptor; HSC, hematopoietic stem cell; HSPC, hematopoietic stem and progenitor cell; I/R, ischemia/reperfusion; MEF, Mouse embryonic fibroblast; MLC, myosin light-chain; MZ, marginal zone; preB, precursor B; proB, progenitor B; Rho, Ras homolog; ROCK, Rho kinase; SBH, subcortical band heterotopia. RhoA cycles between the GDP bound inactive form and the GTP bound active form under the tight control of regulatory GEFs, GAPs, and GDIs. GEFs induce the release of GDP from RhoA and promote GTP binding to RhoA; GAPs stimulate the GTPase activity of RhoA and cause the hydrolysis of RhoA bound GTP; GDIs inhibit the dissociation of GDP from RhoA and also extract RhoA from plasma membranes, preventing RhoA from executing its cellular functions. Upon activation, RhoA can interact with multiple downstream effectors and affect a number of cellular behaviors. An important feature of RhoA signaling is that RhoA activity can be regulated by multiple GEFs, GAPs and GDIs and the physiologic function of RhoA may be mediated through one or several effectors under defined biological contexts. RhoA is essential for the auto-phosphorylation of PKD in response to I/R damage, and this is important to prevent LDH release and heart infarct. C, RhoA regulates lens epithelium morphology. RhoA is activated at the apical half of the lens epithelial cells, and its activity is essential for apical constriction by activating MLC and therefore actomyosin contractility. RhoA activity is also important in restricting Arp2/3 activity, which induces the polymerization of protrusive actin and cell elongation. D, RhoA regulates left-right locomotor circuitry in the developing spinal cord. RhoA is essential for the expression of Ephrin B3 in the midline of developing spinal cord, which in turn is critical for preventing EphA4-expressing corticospinal neurons and spinal interneurons from crossing the midline. E, RhoA regulates hematopoietic progenitor cell survival and differentiation. Through ROCK-MLC cascade and mDia, RhoA controls HPC cytokinesis. Deletion of RhoA in HPCs caused cytokinesis failure and this further induced cell necrosis and a blockade of differentiation. Undefined effectors of RhoA signaling are labeled as "Effector 1", "Effector 2". 
In vivo
No defects of epidermis/hair follicles development; no defects in cell-cell junctions, mitosis and wound healing; increased RhoB expression; reduced phosphorylation of MLC and cofilin (19) .
In vitro
Impaired junction maturation; mild cytokinesis defects; decreased directional migration (19) . Heart Cardiomyocytes (βMHC-Cre) Decreased tolerance to ischemia/reperfusion (I/R) injury; reduced PKD autophosphorylation upon I/R injury (21) . Spinal cord neuroepithelium (Brn4-Cre) Dysplasia and loss of adherens junctions; reduced neuron survival; reduced proliferation and early cell-cycle-exit; premature differentiation of neural progenitors (38) . Dorsal root ganglia (Wnt1-Cre)
Normal projections of DRG sensory neurons; still response to Sema-3 mediated axonal repulsion; increased RhoC expression (46) . Cerebral cortex (Emx1-Cre) Subcortical band heterotopia (SBH) and cobblestone lissencephaly; increased neuron migration; disrupted radial glial scaffold ;wild type neurons migrate abnormally in RhoA null cerebral cortex and also display SBH phenotype; disrupted actin and microtubule cytoskeleton (48) . Hematolymphoid System Hematopoietic stem and progenitor cells (Mx1-Cre) Multi-lineage cytopenia; stem cells still home to the niche and compete normally with wild type cells; loss of progenitor cells; increase of TNFα mediated necrosis in progenitors; cytokinesis failure; reduced MLC phosphorylation but not F-actin polymerization; increased adhesion to fibronectin and reduced migration towards SDF-1α (Submitted). Platelet (PF4-Cre) Increased megakaryocytes but reduced platelet count; reduced life span of platelets; impaired response to G 13 or G q agonist stimulation; prolonged tail bleeding time; protected from ischemic brain infarction (55) . B cells (CD19-Cre) Decreased transitional, marginal zone, and follicular B cells, but not proB and preB cells; reduced BAFF-mediated apoptosis inhibition (58). Embryonic lethality; impaired formation of forebrain and hindbrain, branchial arches and heart; reduced actin stress fiber and focal adhesion (60) . P190 Postnatal lethality; omphalocele; impaired optic fissure closure; failure of callosal axons to extend across the midline; impaired midline fusion; impaired layering of the cerebral cortex; normal cortical neuron migration; exencephaly and neural tube closure defects; accumulation of F-actin along the basal edge of floor plate neuroepithelium; reduced apical constrictions (87) . Axon growth, guidance and fasciculation defects; normal growth cone motility (69). P190B Postnatal lethality; reduced body size; failure of callosal axons to extend across the midline; partial loss of cortical axon tracts; increased fibroblast F-actin; increased RhoA and reduced CREB activity; reduced fibroblast cell size that is rescued by constitutively active CREB or ROCK inhibitor (88) . Cortical thinning and loss of forebrain commissures; dilation of the lateral ventricles; impaired axonal outgrowth and neuronal differentiation (64) . Increased RhoA activity in fetal liver tissues; reduced fetal liver cellularity and blockage of late stage erythropoiesis; reduced fetal liver progenitor cells; increased long-term stem cells; increased homing, migration and adhesion of hematopoietic progenitors; normal survival and proliferation of HSCs (50).
Myo9b
Increased RhoA; reduced macrophage spreading that is recused by RhoA or ROCK inhibitors; reduced macrophage motility; impaired macrophage chemotaxis; reduced generation of membrane lamellipodia protrusion; impaired monocyte recruitment (89) . Effectors: Mediators of RhoA signaling ROCK-I EOB; omphalocele; reduced MLC phosphorylation and actomyosin formation; impaired umbilical ring closure; no defects was observed in skin (74) . Resistant to I/R induced cardiac dysfunction; reduced I/R induced collagen deposition and α-SMA expression; reduced cardiac fibroblasts (90) . Enhanced migration of macrophages and neutrophils in vitro and in vivo; increased recruitment of macrophages and neutrophils into inflamed peritoneum; reduced PTEN phosphorylation, stability and activity; increased activity of PTEN downstream targets such as PIP3, AKT, GSK-3β and cyclin sD1 (75) . ROCK-II Partial embryonic lethality; placenta thrombus; normal actomyosin network in the labyrinth layer and cultured trophoblasts; hind limb hemorrhage (91) . Altered neuronal spine morphology; altered F-actin distribution and reduced basal but not NMDA-induced phosphorylation of cofilin (92) . EOB; reduced actin bundles in extending eyelid (29) . Citron kinase Postnatal lethality; reduced brain size and altered brain structure; reduced cerebral cortex thickness without altered differentiation/ connectivity of cortical neurons; normal cortical neuronal migration; cytokinesis failure; increased apoptosis(71). mDia1
Fertile; reduced splenic T cell; impaired egression of mature T cells from the thymus; reduced chemotaxis of T cells; reduced Factin formation and polarization in response to chemokine stimuli in T cells; impaired T cell proliferation (72) . Age dependent myeloproliferative phenotype; increased monocytes/macrophages in bone marrow and spleen; expansion of erythroid precursors (73) . mDia1 / mDia3 double knockout Normal cortical neuron layer formation and proliferation; increased radial migration; reduced interneuron tangential migration; reduced neuroblasts motility; normal microtubule; impaired movement of F-actin towards the leading process and formation of F-actin cup in the rear of neuroblasts (93) . Dilation of ventricles; impaired neuroepithelium integrity; abnormal apical actin belt and adherens junction; increased cell cycle exit (70) . 
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